Cargando…
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
Neuroblastoma (NB) is the most common extracranial malignant solid tumor seen in children and continues to lead to the death of many pediatric cancer patients. The poor outcome in high risk NB is largely attributed to the development of chemoresistant tumor cells. Doxorubicin (dox) has been widely e...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043366/ https://www.ncbi.nlm.nih.gov/pubmed/27687684 http://dx.doi.org/10.1038/srep34397 |